지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 189 - 195 (7page)
이용수
초록· 키워드
오류제보하기
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations. However, long-term tolerance data are lacking, and cost may be an issue for combination therapies. Several recent, well-designed, randomized controlled trials have shown that TDF monotherapy provides similar antiviral efficacy compared with the combination of TDF and ETV. Furthermore, no additional HBV resistance mutations emerged during TDF monotherapy for up to 96 weeks. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and better safety potential, TDF monotherapy would be a reasonable choice for the treatment of drug-resistant patients with CHB.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Chang TT / 2010 / Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B / Hepatology 51 : 422 ~ 430
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295 : 65 ~ 73
Eun JR / 2010 / Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B v
European Association for the Study of the Liver / 2009 / EASL clinical practice guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Fung SK / 2006 / Virologic response and resistance to adefovir in patients with chronic hepatitis B / J Hepatol 44 : 283 ~ 290
Chen CJ / 2006 / Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level / JAMA 295 : 65 ~ 73
Eun JR / 2010 / Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B v
European Association for the Study of the Liver / 2009 / EASL clinical practice guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Fung SK / 2006 / Virologic response and resistance to adefovir in patients with chronic hepatitis B / J Hepatol 44 : 283 ~ 290
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
Clinical and Molecular Hepatology
2016 .01
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
Kidney Research and Clinical Practice
2020 .01
-
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
Journal of Korean Medical Science
2021 .01
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Clinical and Molecular Hepatology
2015 .01
-
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients
Clinical and Molecular Hepatology
2017 .01
-
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate
Gut and Liver
2019 .01
-
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Clinical and Molecular Hepatology
2021 .01
-
Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity
Kidney Research and Clinical Practice
2018 .01
-
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Journal of Liver Cancer
2021 .09
-
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Gut and Liver
2020 .01
-
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naive patients with chronic hepatitis B
Clinical and Molecular Hepatology
2017 .06
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
Infection and Chemotherapy
2015 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Clinical and Molecular Hepatology
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0